BioCryst BCRX Inks Peramivir Partners

September 15, 2009 - Shares of BioCryst Pharmaceuticals Inc. (BCRX) are on fire in pre market due to the following news. BCRX is Up 7% to $11.50.


BioCryst Announces Partnerships for Peramivir for Influenza Outside the U.S.


BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has signed binding letters of intent with three partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities, as well as for marketing and distribution of peramivir for seasonal influenza upon local regulatory approval, within their territories outside the U.S. Each partner will immediately begin meeting with key government officials in their respective territories to discuss peramivir's availability during this global health emergency.
BioCryst's new partners include:

- moksha8 Pharmaceuticals, Inc. for Brazil and Mexico

- NT Pharma (Group) Co., Ltd. for China

- Neopharm Group for Israel

Full Article


For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free